[go: up one dir, main page]

WO2025234781A1 - Préparation d'association contenant de l'ézétimibe, de la rosuvastatine et de l'empagliflozine avec observance thérapeutique améliorée - Google Patents

Préparation d'association contenant de l'ézétimibe, de la rosuvastatine et de l'empagliflozine avec observance thérapeutique améliorée

Info

Publication number
WO2025234781A1
WO2025234781A1 PCT/KR2025/006173 KR2025006173W WO2025234781A1 WO 2025234781 A1 WO2025234781 A1 WO 2025234781A1 KR 2025006173 W KR2025006173 W KR 2025006173W WO 2025234781 A1 WO2025234781 A1 WO 2025234781A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
pharmaceutical combination
combination preparation
empagliflozin
rosuvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2025/006173
Other languages
English (en)
Korean (ko)
Inventor
김보식
이광영
김지은
권택관
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of WO2025234781A1 publication Critical patent/WO2025234781A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a combination preparation comprising ezetimibe, rosuvastatin, and empagliflozin with improved medication compliance.
  • Diabetics are two to four times more likely to die from cardiovascular disease. Cardiovascular disease accounts for 60 to 80% of all deaths among diabetic patients, making it a significant risk factor. For every 39 mg/dL increase in LDL cholesterol, the risk of developing coronary artery disease increases by approximately 60%. Therefore, active treatment is necessary when dyslipidemia is present.
  • Dyslipidemia Fact Sheet patients with diabetes are at a significantly higher risk of dyslipidemia than those without diabetes, with approximately 90% of people with diabetes aged 20 years and older having dyslipidemia. Approximately 48% of people with diabetes have LDL cholesterol levels above 100 mg/dL, highlighting the need for active concurrent management.
  • the combination preparation of ezetimibe/rosuvastatin is known as a combination preparation of drugs related to cardiovascular diseases such as amlodipine and/or losartan, as in patent document 1, but has not yet been suggested for a combination with empagliflozin, a diabetes treatment drug.
  • Patent Document 2 proposes a combination formulation comprising ezetimibe, pitavastatin, and the DPP-4 inhibitor linagliptin, as a treatment for metabolic diseases such as dyslipidemia or diabetes.
  • Empagliflozin is an SGLT-2 inhibitor and belongs to a different class of drugs than the aforementioned DPP-4 inhibitors, and a combination formulation containing ezetimibe, rosuvastatin, and empagliflozin has not yet been proposed.
  • the present inventors sought to develop a combination formulation containing both dyslipidemia and diabetes treatment agents, and furthermore, by considering the sites of action of these drugs, developed a combination formulation form of the present invention that can secure a high dissolution rate of all three components while also having excellent stability, thereby completing the present invention.
  • Patent Document 1 KR Registered Patent No. 10-2569271
  • Patent Document 2 KR Registered Patent No. 10-2289381
  • One object of the present invention is to provide an oral combination formulation that contains ezetimibe, rosuvastatin, and empagliflozin as active ingredients, thereby having a synergistic effect in the concomitant treatment of dyslipidemia and diabetes, while also having a dissolution profile equivalent to that of single administration of these drugs individually, and also having excellent stability.
  • Another object of the present invention is to provide a method for efficiently manufacturing the oral administration combination preparation provided by the present invention.
  • the present invention relates to a pharmaceutical combination preparation comprising (1) ezetimibe or a pharmaceutically acceptable salt thereof, (2) rosuvastatin or a pharmaceutically acceptable salt thereof, and (3) empagliflozin or a pharmaceutically acceptable salt thereof as active ingredients.
  • the above empagliflozin may be included in an amount of 1.5 to 8 wt% based on the total weight of the pharmaceutical combination preparation.
  • the above pharmaceutical combination preparation may contain ezetimibe in an amount of 5 to 20 mg per unit dosage form, rosuvastatin in an amount of 2 to 20 mg, and empagliflozin in an amount of 5 to 40 mg.
  • the above pharmaceutical combination preparation may contain ezetimibe in an amount of 5 to 20 mg per unit dosage form, rosuvastatin in an amount of 2.5 to 20 mg, and empagliflozin in an amount of 10 to 25 mg.
  • the pharmaceutical combination formulation may contain ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 to 10 mg, and empagliflozin in an amount of 10 or 25 mg.
  • the above pharmaceutical combination preparation may contain a disintegrant in an amount of 1 to 15 wt% based on the total weight of the pharmaceutical combination preparation.
  • the disintegrant may be selected from the group consisting of crospovidone, croscarmellose sodium, sodium starch glycolate methylcellulose, cross-linked carboxymethylcellulose sodium (Cross-linked CMC Na, C.CMC Na, or croscarmellose sodium), carboxymethylcellulose calcium, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, pregelatinized starch, alginic acid or its sodium salt, and combinations thereof.
  • the above pharmaceutical combination preparation may contain excipients in an amount of 60 to 95 wt% based on the total weight of the pharmaceutical combination preparation.
  • the above excipient may include at least one selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminosilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose hydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate hydrate, calcium carbonate, and sugars.
  • the above pharmaceutical combination preparation may further include an active agent in an amount of 0.1 to 10 wt% based on the total weight of the pharmaceutical preparation, and a binder in an amount of 0.1 to 5 wt%.
  • the ezetimibe or a pharmaceutically acceptable salt thereof may be physically separated from the rosuvastatin or a pharmaceutically acceptable salt thereof and the empagliflozin or a pharmaceutically acceptable salt thereof.
  • the above pharmaceutical combination preparation may include a granular portion comprising ezetimibe or a pharmaceutically acceptable salt thereof; and a postmixed portion comprising rosuvastatin or a pharmaceutically acceptable salt thereof and empagliflozin or a pharmaceutically acceptable salt thereof.
  • Empagliflozin in the above post-mixing unit may be included in an amount of 0.5 to 11 wt% based on the total weight of the above post-mixing unit.
  • the above post-mixing unit may contain excipients in an amount of 60 to 97 wt% based on the total weight of the post-mixing unit.
  • the above post-mixing portion may contain excipients in an amount of 60 to 90 wt% based on the total weight of the pharmaceutical combination preparation.
  • the above post-mixing unit may contain a disintegrant in an amount of 0.1 to 15 wt% based on the total weight of the pharmaceutical combination preparation.
  • the above granular portion may contain a disintegrant in an amount of 0.5 to 5 wt% based on the total weight of the pharmaceutical combination preparation.
  • the above pharmaceutical combination preparation may have a dissolution rate of rosuvastatin of 70% or more within 5 minutes, 85% or more within 15 minutes, and 90% or more within 30 minutes in a dissolution test (pH 1.2 solution, 37°C, 900 mL, 50 rpm).
  • the above pharmaceutical combination preparation may have a dissolution rate (based on weight) of empagliflozin of 50% or more within 5 minutes, 80% or more within 15 minutes, and 85% or more within 30 minutes in a dissolution test (pH 1.2 solution, 37°C, 900 mL, 50 rpm).
  • a method for preparing a pharmaceutical combination preparation comprising the steps of: (a) preparing a granular portion comprising ezetimibe or a pharmaceutically acceptable salt thereof as an active ingredient; (b) preparing a postmixed portion comprising rosuvastatin or a pharmaceutically acceptable salt thereof and empagliflozin or a pharmaceutically acceptable salt thereof as active ingredients; and (c) mixing the granular portion and the postmixed portion to prepare a solid preparation.
  • the above empagliflozin can be mixed in an amount of 1.5 to 8 wt% based on the total weight of the pharmaceutical combination preparation.
  • a disintegrant may be added during at least one of the steps of (a) preparing the granule portion; and (b) preparing the post-mixing portion.
  • the above disintegrant may be added in an amount of 1 to 15 wt% based on the total weight of the pharmaceutical combination preparation.
  • the combination formulation provided by the present invention contains ezetimibe, rosuvastatin, and empagliflozin as active ingredients, thereby having a synergistic effect in the concomitant treatment of dyslipidemia and diabetes, while also securing a dissolution profile equivalent to that of single administration of these drugs individually, and providing an oral combination formulation with excellent stability.
  • the oral combination formulation of the present invention can administer two drugs that are conventionally administered in combination in a single formulation, thereby enabling simultaneous management of risk factors in patients and improving medication compliance.
  • the oral combination formulation of the present invention has excellent friability, thereby enhancing tabletability and moisture stability, thereby preventing a decrease in productivity.
  • Figure 1 is a drawing showing the results of an experiment comparing the dissolution rates of empagliflozin under the conditions of a pH 1.2 solution, targeting Examples 1 to 3 and Comparative Examples 1 and 2 in Experimental Example 1 and the control drug, Control Example 2.
  • Figure 2 is a drawing showing the results of an experiment comparing the dissolution rates of rosuvastatin under conditions of a pH 1.2 solution, targeting Examples 1 to 3 and Comparative Examples 1 and 2 in Experimental Example 1 and the control drug, Control Example 1.
  • Figure 3 is a drawing showing the results of an experiment comparing the dissolution rates of empagliflozin under the conditions of a pH 1.2 solution for the tablets of Examples 2 and 4 to 8 in Experimental Example 2.
  • Figure 4 is a drawing showing the results of an experiment comparing the dissolution rates of rosuvastatin under the conditions of a pH 1.2 solution, targeting the tablets of Examples 2 and 4 to 8 in Experimental Example 2.
  • Figure 5 is a drawing showing the results of an experiment comparing the dissolution rates of ezetimibe in the tablets of Example 2 and Examples 4 to 8 under the condition of a pH 6.8 solution in Experimental Example 2.
  • Figure 6 is a drawing showing the results of an experiment comparing the dissolution rates of empagliflozin under pH 1.2 solution conditions, targeting the tablets of Examples 2, 9 to 11, and Comparative Example 3 in Experimental Example 3 and the control drug, Control Example 2.
  • Figure 7 is a drawing showing the results of an experiment comparing the dissolution rates of rosuvastatin under conditions of a pH 1.2 solution, targeting the tablets of Examples 2, 9 to 11, and Comparative Example 3 in Experimental Example 3 and the control drug, Control Example 1.
  • Figure 8 is a graph showing the change in plasma concentration (ng/mL) of ezetimibe over time as a result of evaluating the pharmacokinetic parameters of ezetimibe after administering the tablet of Example 2 to a beagle dog in Experimental Example 5 or administering the tablets of Control Examples 1 and 2 together.
  • Figure 9 is a graph showing the change in the plasma concentration (ng/mL) of rosuvastatin over time as a result of evaluating the pharmacokinetic parameters of rosuvastatin after administering the tablet of Example 2 to a beagle dog in Experimental Example 5 or administering the tablets of Control Examples 1 and 2 together.
  • Figure 10 is a graph showing the change in the plasma concentration (ng/mL) of empagliflozin over time as a result of the evaluation of the pharmacokinetic parameters of empagliflozin after administering the tablet of Example 2 to a beagle dog in Experimental Example 5 or administering the tablets of Control Examples 1 and 2 together.
  • a pharmaceutical combination preparation comprising (1) ezetimibe or a pharmaceutically acceptable salt thereof, (2) rosuvastatin or a pharmaceutically acceptable salt thereof, and (3) empagliflozin or a pharmaceutically acceptable salt thereof as active ingredients.
  • a method for preparing a pharmaceutical combination preparation comprising the steps of: (a) preparing a granular portion comprising ezetimibe or a pharmaceutically acceptable salt thereof as an active ingredient; (b) preparing a postmixed portion comprising rosuvastatin or a pharmaceutically acceptable salt thereof and empagliflozin or a pharmaceutically acceptable salt thereof as active ingredients; and (c) mixing the granular portion and the postmixed portion to prepare a solid preparation.
  • diabetes and dyslipidemia typically take a large number of medications, often with multiple types and durations, increasing the burden of medication. Furthermore, diabetes and dyslipidemia have a high co-morbidity, meaning patients with both conditions face the burden of having to take medications for each condition separately.
  • the active ingredients of ezetimibe and rosuvastatin, which are effective in treating dyslipidemia, and empagliflozin, which is effective in treating diabetes are included in a single formulation, thereby enabling concurrent treatment of dyslipidemia and diabetes with only one formulation, and the number of medications that a patient must take is reduced, thereby improving convenience of taking the medication and compliance with medication.
  • the present invention relates to a pharmaceutical combination preparation comprising (1) ezetimibe or a pharmaceutically acceptable salt thereof, (2) rosuvastatin or a pharmaceutically acceptable salt thereof, and (3) empagliflozin or a pharmaceutically acceptable salt thereof as active ingredients.
  • the "ezetimibe” is a compound of (3R,4S)-1-(4-fluorophenyl)-3-[(S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one represented by the following chemical formula 1.
  • the ezetimibe is known to lower blood lipid-related levels by preventing cholesterol ingested through food from being reabsorbed into the body in the small intestine.
  • the "rosuvastatin” is a compound of (E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid) represented by the following chemical formula 2.
  • the rosuvastatin is known to inhibit HMG-CoA reductase, which is essential for the cholesterol synthesis process, thereby lowering blood LDL-cholesterol levels and, conversely, increasing HDL-cholesterol levels, thereby contributing to the treatment of dyslipidemia.
  • epipagliflozin is a compound of (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol) represented by the following chemical formula 3.
  • the empagliflozin inhibits SGLT-2 in the renal tubules, thereby inhibiting the reabsorption process of glucose and excreting glucose in the urine, thereby suppressing an increase in blood sugar levels.
  • pharmaceutically acceptable salt refers to a salt commonly used in the relevant technical field, and includes not only salts prepared with inorganic ions, inorganic acids or organic acids, but also hydrates or solvates of the salts.
  • pharmaceutically acceptable salts of ezetimibe, rosuvastatin or empagliflozin include acetate, adipate, L-ascorbate, L-aspartate, caprate, carbonate, citrate, fumarate, mucosal salt, D-glucoheptone, D-gluconate, D-glucuronate, glutamate, glutarate, glycerophosphate, glycolate, hippurate, hydrochloride, DL-lactate, laurate, maleate, (-)-L-malic acid, palmitate, phosphate, sebacate, stearate, succinate, sulfate, (+)-L-tartrate, thiocyanate, alginic acid, benzenesulfonate, benzoate, (+)-camphorate, caprylate, cyclamate, dodecylsulfate, ethane-1,2-disulfonate, Examples thereof include, but are not limited
  • pharmaceutically acceptable salts of rosuvastatin include calcium salts, magnesium salts, zinc salts, strontium salts, etc., and are preferably rosuvastatin calcium salts, but are not limited thereto.
  • the empagliflozin may be used together with one or more amino acids.
  • the amino acid may be selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, serine, cysteine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, histidine, and lysine.
  • the empagliflozin and the amino acid may be in the form of a co-crystal.
  • the active ingredient may include, but is not limited to, empagliflozin and proline (e.g., L-proline or D-proline).
  • ezetimibe any reference in this specification to “ezetimibe,” “rosuvastatin,” and “empagliflozin” should be understood to include all salts, solvates, and isomers of each of the above-mentioned compounds.
  • the combination formulation of the present invention may contain ezetimibe in an amount of 5 mg to 20 mg per unit dosage form, and preferably in an amount of 5 mg to 15 mg.
  • the pharmaceutical formulation of the present invention may contain ezetimibe as an active ingredient in an amount of 10 mg, but is not limited thereto.
  • the content refers to the amount contained as ezetimibe in a free state, i.e., not in the form of an inorganic or organic salt, ester, hydrate, or solvate.
  • the combination preparation of the present invention may contain rosuvastatin in an amount of 2 mg to 40 mg or 2 to 20 mg per unit dosage form, and preferably 2.5 mg to 40 mg or 2.5 mg to 20 mg.
  • the pharmaceutical preparation of the present invention may contain rosuvastatin as an active ingredient in an amount of, but not limited to, 2.5 mg, 5 mg, 10 mg, or 20 mg.
  • the content refers to the amount contained as rosuvastatin in a free state, i.e., not in the form of an inorganic or organic salt, ester, hydrate, or solvate.
  • the pharmaceutical preparation of the present invention may contain rosuvastatin calcium salt as an active ingredient in an amount of, but not limited to, 2.6 mg, 5.2 mg, 10.4 mg, or 20.8 mg.
  • the content at this time refers to the amount contained as rosuvastatin calcium salt.
  • the combination preparation of the present invention may contain empagliflozin in an amount of 5 mg to 40 mg or 10 to 40 mg per unit dosage form, and preferably 5 mg to 25 mg or 10 mg to 25 mg.
  • the pharmaceutical preparation of the present invention may contain empagliflozin as an active ingredient in an amount of, but not limited to, 10 mg, 12.5 mg, 15 mg, 20 mg or 25 mg.
  • the content refers to the amount contained as empagliflozin in a free state, i.e., not in the form of an inorganic or organic salt, ester, hydrate or solvate.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 5 mg to 20 mg, rosuvastatin in an amount of 2 mg to 40 mg, and empagliflozin in an amount of 5 mg to 40 mg per unit dosage form.
  • the combination formulation of the present invention may contain, but is not limited to, ezetimibe in an amount of 5 mg to 15 mg, rosuvastatin in an amount of 2 mg to 20 mg, and empagliflozin in an amount of 5 mg to 40 mg per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 5 mg to 20 mg, rosuvastatin in an amount of 2.5 mg to 20 mg, and empagliflozin in an amount of 10 mg to 25 mg per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 5 mg to 15 mg, rosuvastatin in an amount of 2.5 mg to 20 mg, and empagliflozin in an amount of 10 mg to 25 mg per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg, rosuvastatin in an amount of 2.5 mg to 20 mg, and empagliflozin in an amount of 10 mg or 25 mg per unit dosage form.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, 5 mg, 10 mg, or 20 mg, and empagliflozin in an amount of 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg, but is not limited thereto.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, 5 mg or 10 mg, and empagliflozin in an amount of 10 mg, 12.5 mg, 15 mg, 20 mg or 25 mg, but is not limited thereto.
  • the combination formulation of the present invention may comprise, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, 5 mg, 10 mg or 20 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may comprise, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, 5 mg or 10 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, and empagliflozin in an amount of, but not limited to, 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 5 mg, and empagliflozin in an amount of, but not limited to, 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 10 mg, and empagliflozin in an amount of 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg, but is not limited thereto.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 5 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 10 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, 5 mg or 10 mg, and empagliflozin in an amount of 10 mg.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin in an amount of 2.5 mg, 5 mg or 10 mg, and empagliflozin in an amount of 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 2.5 mg of rosuvastatin, and 10 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 5 mg of rosuvastatin, and 10 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 10 mg of rosuvastatin, and 10 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 2.5 mg of rosuvastatin, and 25 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 5 mg of rosuvastatin, and 25 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 10 mg of rosuvastatin, and 25 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may contain, but is not limited to, ezetimibe in an amount of 5 mg to 15 mg, rosuvastatin calcium salt in an amount of 2.6 mg to 20.8 mg, and empagliflozin in an amount of 10 mg to 25 mg per unit dosage form.
  • the combination formulation of the present invention may contain, but is not limited to, 10 mg of ezetimibe, 2.6 mg to 20.8 mg of rosuvastatin calcium salt, and 10 mg or 25 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may contain, but is not limited to, ezetimibe in an amount of 5 mg to 20 mg, rosuvastatin calcium salt in an amount of 2.6 mg to 20.8 mg, and empagliflozin in an amount of 5 mg to 25 mg per unit dosage form.
  • the combination formulation of the present invention may contain, but is not limited to, ezetimibe in an amount of 5 mg to 15 mg per unit dosage form, rosuvastatin in an amount of 2.6 mg to 10.4 mg as a calcium salt, and empagliflozin in an amount of 10 mg to 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, 5.2 mg, 10.4 mg, or 20.8 mg, and empagliflozin in an amount of, but not limited to, 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, 5.2 mg or 10.4 mg, and empagliflozin in an amount of 10 mg, 12.5 mg, 15 mg, 20 mg or 25 mg, but is not limited thereto.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, 5.2 mg, 10.4 mg or 20.8 mg, and empagliflozin in an amount of 10 mg or 25 mg, but is not limited thereto.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, 5.2 mg or 10.4 mg, and empagliflozin in an amount of 10 mg or 25 mg, but is not limited thereto.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, and empagliflozin in an amount of, but not limited to, 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 5.2 mg, and empagliflozin in an amount of, but not limited to, 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 10.4 mg, and empagliflozin in an amount of, but not limited to, 10 mg, 12.5 mg, 15 mg, 20 mg, or 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 5.2 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 10.4 mg, and empagliflozin in an amount of 10 mg or 25 mg.
  • the combination formulation of the present invention may comprise ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, 5.2 mg or 10.4 mg, and empagliflozin in an amount of 10 mg, but is not limited thereto.
  • the combination formulation of the present invention may comprise, but is not limited to, ezetimibe in an amount of 10 mg per unit dosage form, rosuvastatin calcium salt in an amount of 2.6 mg, 5.2 mg, or 10.4 mg, and empagliflozin in an amount of 25 mg.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 2.6 mg of rosuvastatin calcium salt, and 10 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 5.2 mg of rosuvastatin calcium salt, and 10 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 10.4 mg of rosuvastatin calcium salt, and 10 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 2.6 mg of rosuvastatin calcium salt, and 25 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 5.2 mg of rosuvastatin calcium salt, and 25 mg of empagliflozin per unit dosage form.
  • the combination formulation of the present invention may include, but is not limited to, 10 mg of ezetimibe, 10.4 mg of rosuvastatin calcium salt, and 25 mg of empagliflozin per unit dosage form.
  • the combination preparation of the present invention may contain ezetimibe in an amount of 1 to 3 wt%, 1 to 2.5 wt%, 1 to 2 wt%, 1.5 to 3 wt%, 1.5 to 2.5 wt%, or 1.5 to 2 wt% based on the total weight of the combination preparation.
  • the combination preparation of the present invention may contain rosuvastatin or a pharmaceutically acceptable salt thereof, preferably rosuvastatin calcium salt, in an amount of 0.1 to 3 wt%, 0.1 to 2.5 wt%, 0.1 to 2.2 wt%, 0.5 to 3 wt%, 0.5 to 2.5 wt%, or 0.5 to 2.2 wt% based on the total weight of the combination preparation.
  • the combination preparation of the present invention may contain empagliflozin in an amount of 1.5 to 8 wt%, 1.5 to 7.5 wt%, 1.5 to 7 wt%, 1.5 to 6 wt%, or 1.5 to 5 wt% based on the total weight of the combination preparation.
  • the dissolution stability may be reduced, and it may be difficult to expect the target dissolution rate, that is, the same level as the dissolution rate obtained when each component is administered as a single drug.
  • the combination preparation of the present invention can increase the dissolution stability of the active ingredients and also improve the physical stability of the preparation itself by including a disintegrant together with the above-mentioned active ingredients in an amount of 1 to 15 wt%, 1 to 12 wt%, 1 to 10 wt%, 1 to 5 wt%, 2 to 15 wt%, 2 to 12 wt%, 2 to 10 wt%, or 2 to 5 wt% based on the total weight of the pharmaceutical combination preparation.
  • the content of the disintegrant is less than 1 wt%, the dissolution rate of the active ingredient may decrease, and when the content exceeds 15 wt%, the physical stability of the preparation may decrease.
  • the disintegrant may be selected from the group consisting of crospovidone, croscarmellose sodium, sodium starch glycolate, carboxymethylcellulose calcium, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or a sodium salt thereof, and any combination thereof, and preferably may include at least one of crospovidone, croscarmellose sodium, and sodium starch glycolate, but is not limited thereto.
  • L-HPC low-substituted hydroxypropylcellulose
  • the complex preparation of the present invention may additionally include one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), lubricants, and binders.
  • the combined preparation of the present invention may contain an excipient (diluent) in an amount of 60 to 95 wt%, 60 to 90 wt%, 65 to 95 wt%, 65 to 90 wt%, 70 to 95 wt%, 70 to 90 wt%, 75 to 95 wt%, 75 to 90 wt%, 78 to 95 wt%, or 78 to 90 wt% based on the total weight of the pharmaceutical preparation, but is not limited thereto.
  • an excipient in an amount of 60 to 95 wt%, 60 to 90 wt%, 65 to 95 wt%, 65 to 90 wt%, 70 to 95 wt%, 70 to 90 wt%, 75 to 95 wt%, 75 to 90 wt%, 78 to 95 wt%, or 78 to 90 wt% based on the total weight of the pharmaceutical preparation, but is not limited thereto.
  • the excipient may include a substance selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminosilicate metasilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose hydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate hydrate, calcium carbonate, sugars, and any mixture thereof, but is not limited thereto. Any substance used as an excipient (diluent) in the art may be included without limitation.
  • the combined preparation of the present invention may contain the lubricant in an amount of 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1.5 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, 0.5 to 3 wt%, 0.5 to 2 wt%, or 0.5 to 1.5 wt% based on the total weight of the pharmaceutical preparation, but is not limited thereto.
  • the lubricant may be selected from the group consisting of calcium stearate, colloidal silicon dioxide (fumed silica, Aerosil), glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hardened vegetable oil, polyethylene glycol, sodium benzoate, talc, and any combination thereof, but is not limited thereto, and any substance used as a lubricant in the art may be included without limitation.
  • the combination preparation of the present invention may contain a binder in an amount of 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1 wt%, or 0.1 to 0.6 wt% based on the total weight of the pharmaceutical preparation, but is not limited thereto.
  • the binder when only a solvent is used in the wet granulation of the granule portion, the binder may not be included.
  • the composite preparation of the present invention may include a granular portion and a post-mixed portion, and in this case, the granular portion and the post-mixed portion may be mixed and present in the composite preparation.
  • the granular portion means a state in which a plurality of components are mixed to form a plurality of granules, and may include both dry granules and wet granules, but may preferably be wet granules.
  • one of the three active ingredients and the other two active ingredients can be physically separated.
  • the ezetimibe may exist in a physically separated state from rosuvastatin and empagliflozin.
  • the active ingredients, ezetimibe and rosuvastatin/empagliflozin may have problems with the stability of the active ingredients, such as an increase in related substances of ezetimibe and rosuvastatin/empagliflozin, due to differences in their stable pH conditions when formulated as a combination preparation. Accordingly, it may be preferable for the ezetimibe and rosuvastatin/empagliflozin to exist in a physically separated state.
  • the term "physically separated state” refers to a processing step for separating a reference active ingredient from other active ingredients, and a state in which the reference active ingredient is maintained in a state distinguishable from other active ingredients in the final combination preparation obtained through such a processing step. This does not apply to a case in which the components themselves are mixed in a mixing process in advance without such a processing step.
  • a physically separated state can be formed through, for example, physical separation using granule manufacturing, physical separation by dividing the layers and pressing them into tablets, physical separation by pressing them into separate tablets, and physical separation using a core-shell structure.
  • the granular portion may include ezetimibe or a pharmaceutically acceptable salt thereof
  • the post-mixed portion may include rosuvastatin or a pharmaceutically acceptable salt thereof and empagliflozin or a pharmaceutically acceptable salt thereof.
  • the granular portion may include rosuvastatin or a pharmaceutically acceptable salt thereof and empagliflozin or a pharmaceutically acceptable salt thereof, and the post-mixed portion may include ezetimibe or a pharmaceutically acceptable salt thereof.
  • the granular portion or the post-mixing portion may additionally include one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, binders, and lubricants.
  • At least one of the granular portion and the post-mixing portion may include a disintegrant.
  • the granular portion may include a disintegrant
  • the post-mixing portion may include a disintegrant
  • both the granular portion and the post-mixing portion may include a disintegrant.
  • the granular portion contains ezetimibe or a pharmaceutically acceptable salt thereof as an active ingredient, and may additionally contain one or more pharmaceutically acceptable additives selected from the group consisting of excipients (diluents), disintegrants, lubricants, and binders.
  • ezetimibe which is included as an active ingredient in the granular portion, may be included in an amount of 10 to 30 wt%, 10 to 20 wt%, or 10 to 15 wt% based on the total weight of the granular portion, but is not limited thereto.
  • the granular portion may further include a disintegrant.
  • the content of the disintegrant included in the granular portion may be included in an amount of 0.5 to 5 wt%, 0.5 to 4 wt%, 0.5 to 3 wt%, 0.5 to 2 wt%, 1 to 5 wt%, 1 to 4 wt%, 1 to 3 wt%, or 1 to 2 wt% based on the total weight of the pharmaceutical combination preparation.
  • the content is less than 0.5 wt%, the dissolution rate of the active ingredient may decrease, and when the content exceeds 5 wt%, the friability of the preparation may decrease, which may significantly deteriorate the tableting properties or the stability of the drug due to moisture.
  • the content of the disintegrant included in the granular portion may be included in an amount of 3 to 20 wt%, 3 to 15 wt%, 3 to 10 wt%, 5 to 15 wt%, or 5 to 10 wt% based on the total weight of the granular portion. If the content of the disintegrant in the granular portion is less than 3 wt%, the dissolution rate of the active ingredient may decrease, and if the content exceeds 20 wt%, the friability of the formulation may decrease, resulting in a significant decrease in tableting properties or drug stability due to moisture.
  • the disintegrant included in the granular portion may be selected from the group consisting of crospovidone, croscarmellose sodium, sodium starch glycolate, carboxymethylcellulose calcium, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or a sodium salt thereof, and any combination thereof, and preferably may include at least one of crospovidone, croscarmellose sodium, and sodium starch glycolate, but is not limited thereto.
  • L-HPC low-substituted hydroxypropylcellulose
  • the granular portion may further include an excipient (diluent).
  • the content of the excipient (diluent) in the granular portion may be included in an amount of 5 to 20 wt%, 5 to 15 wt%, 10 to 25 wt%, 10 to 20 wt%, or 10 to 15 wt% based on the total weight of the pharmaceutical combination preparation, but is not limited thereto.
  • the granular portion may contain an excipient (diluent) in an amount of 50 to 80 wt%, 60 to 80 wt%, or 70 to 80 wt% based on the total weight of the granular portion, but is not limited thereto.
  • the excipient (diluent) included in the granular portion may include a substance selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminometasilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose monohydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate monohydrate, calcium carbonate, sugars, and any mixture thereof, but is not limited thereto. Any substance used as an excipient (diluent) in the art may be included without limitation.
  • the granular portion may further include a lubricant.
  • the lubricant included in the granular portion may be included in an amount of 0.05 to 5 wt%, 0.05 to 3 wt%, 0.05 to 2 wt%, 0.05 to 1 wt%, 0.05 to 0.5 wt%, 0.1 to 5 wt%, 0.1 to 2 wt%, 0.1 to 3 wt%, 0.1 to 1 wt%, or 0.1 to 0.5 wt% based on the total weight of the pharmaceutical combination preparation, but is not limited thereto.
  • the lubricant included in the granular portion in the present invention may be included in an amount of 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, 0.5 to 3 wt%, or 0.5 to 2 wt% based on the total weight of the granular portion, but is not limited thereto.
  • the lubricant included in the granular portion may be selected from the group consisting of calcium stearate, colloidal silicon dioxide (fumed silica, Aerosil), glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid, hardened vegetable oil, polyethylene glycol, sodium benzoate, talc, and any combination thereof, but is not limited thereto, and any material used as a lubricant in the art may be included without limitation.
  • colloidal silicon dioxide fumed silica, Aerosil
  • glyceryl monostearate glyceryl palmitostearate
  • magnesium stearate sodium lauryl sulfate
  • sodium stearyl fumarate sodium stearyl fumarate
  • zinc stearate zinc stearate
  • stearic acid hardened vegetable oil
  • polyethylene glycol sodium benzo
  • the granular portion may further include a binder for producing wet granules.
  • the binder included in the granular portion may be included in an amount of 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1 wt%, or 0.1 to 0.6 wt% based on the total weight of the pharmaceutical combination preparation, but is not limited thereto.
  • the binder included in the granular portion in the present invention may be included in an amount of 0.5 to 10 wt%, 0.5 to 5 wt%, 0.5 to 3 wt%, 1 to 10 wt%, 1 to 5 wt%, or 1 to 3 wt% based on the total weight of the granular portion, but is not limited thereto.
  • a binder when only a solvent is used for binding when manufacturing wet granules using the granule portion, a binder may not be included.
  • the binder included in the granular portion may be selected from the group consisting of povidone, hypromellose, hydroxypropylcellulose, copovidone, and any combination thereof, but is not limited thereto, and any material used as a binder in the art may be included without limitation.
  • the granular portion may further include, in addition to the active ingredient, an additive selected from among microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, sodium lauryl sulfate, and any combination thereof, as a pharmaceutically acceptable additive.
  • an additive selected from among microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, povidone, sodium lauryl sulfate, and any combination thereof, as a pharmaceutically acceptable additive.
  • the post-mixing portion includes, as active ingredients, rosuvastatin or a pharmaceutically acceptable salt thereof and empagliflozin or a pharmaceutically acceptable salt thereof, and may further include one or more pharmaceutically acceptable additives selected from the group consisting of a disintegrant, an excipient (diluent), and a lubricant.
  • rosuvastatin included as an active ingredient in the post-mixing portion may be included in an amount of 0.1 to 10 wt%, 0.1 to 8 wt%, 0.1 to 6 wt%, 0.1 to 3 wt%, 0.5 to 10 wt%, 0.5 to 8 wt%, 0.5 to 6 wt%, 0.5 to 3 wt%, 1 to 10 wt%, 1 to 8 wt%, 1 to 6 wt%, or 1 to 3 wt%, based on the total weight of the post-mixing portion, but is not limited thereto.
  • the rosuvastatin calcium salt may be included in an amount of 0.1 to 10 wt%, 0.1 to 8 wt%, 0.1 to 6 wt%, 0.1 to 3 wt%, 0.5 to 10 wt%, 0.5 to 8 wt%, 0.5 to 6 wt%, 0.5 to 3 wt%, 1 to 10 wt%, 1 to 8 wt%, 1 to 6 wt%, or 1 to 3 wt% based on the total weight of the post-mixing portion, but is not limited thereto.
  • empagliflozin included as an active ingredient in the post-mixing portion may be included in an amount of 0.5 to 11 wt%, 0.5 to 10 wt%, 0.5 to 8 wt%, 0.5 to 6 wt%, 1 to 11 wt%, 1 to 10 wt%, 1 to 8 wt%, 1 to 6 wt%, 1.5 to 11 wt%, 1.5 to 10 wt%, 1.5 to 8 wt%, or 1.5 to 6 wt%, based on the total weight of the post-mixing portion, but is not limited thereto.
  • Empagliflozin itself has sticky properties as a raw material. Therefore, it is important to control the content range when manufacturing a formulation.
  • the post-mixing unit may further include a disintegrant.
  • the content of the disintegrant included in the post-mixing unit may be included in an amount of 0.1 to 15 wt%, 0.1 to 10 wt%, 0.1 to 8 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, 1 to 10 wt%, 1 to 8 wt%, 1 to 5 wt%, or 1 to 3 wt% based on the total weight of the pharmaceutical combination preparation.
  • the content of the disintegrant is less than 0.5 wt%, the dissolution rate of the active ingredient may decrease, and when the content exceeds 15 wt%, the friability of the preparation may decrease, which may significantly deteriorate the tableting properties or the stability of the drug due to moisture.
  • the disintegrant included in the post-mixing section may be included in an amount of 0.1 to 18 wt%, 0.1 to 15 wt%, 0.1 to 12 wt%, 0.1 to 7 wt%, 0.1 to 5 wt%, 0.5 to 18 wt%, 0.5 to 15 wt%, 0.5 to 12 wt%, 0.5 to 7 wt%, 0.5 to 5 wt%, 1 to 18 wt%, 1 to 15 wt%, 1 to 12 wt%, 1 to 7 wt%, or 1 to 5 wt% based on the total weight of the post-mixing section, but is not limited thereto.
  • the content of the disintegrant is less than 0.1 wt%, the dissolution rate of the active ingredient may decrease, and if the content exceeds 18 wt%, the friability of the formulation may decrease, resulting in a significant decrease in tableting properties or drug stability due to moisture.
  • the disintegrant included in the post-mixing portion may be selected from the group consisting of crospovidone, croscarmellose sodium, sodium starch glycolate, carboxymethylcellulose calcium, hydroxypropylcellulose, low-substituted hydroxypropylcellulose (L-HPC), hydroxypropylmethylcellulose, starch, pregelatinized starch, corn starch, potato starch, alginic acid or a sodium salt thereof, and any combination thereof, and preferably may include at least one of crospovidone, croscarmellose sodium, and sodium starch glycolate, but is not limited thereto.
  • L-HPC low-substituted hydroxypropylcellulose
  • the post-mixing unit may further include an excipient (diluent).
  • the content of the excipient (diluent) in the post-mixing unit may be included in an amount of 50 to 90 wt%, 50 to 85 wt%, 50 to 80 wt%, 60 to 90 wt%, 60 to 85 wt%, 60 to 80 wt%, 70 to 90 wt%, 70 to 85 wt%, or 70 to 80 wt% based on the total weight of the pharmaceutical preparation, but is not limited thereto.
  • the excipient (diluent) included in the post-mixing unit may be included in an amount of 60 to 97 wt%, 60 to 95 wt%, 70 to 97 wt%, 70 to 95 wt%, 75 to 97 wt%, 75 to 95 wt%, 80 to 97 wt%, or 80 to 95 wt%, based on the total weight of the post-mixing unit, but is not limited thereto.
  • the content of the excipient (diluent) in the post-mixing unit is related to the dissolution rate of empagliflozin.
  • the content of the excipient is less than 60 wt%, the dissolution is delayed due to the sticky and easily aggregated nature of empagliflozin, and the dissolution of rosuvastatin mixed together may be inhibited.
  • the content of excipients exceeds 97 wt%, it may increase the generation of flexible substances or rather suppress the release of the drug.
  • the excipient (diluent) included in the post-mixing section may include, but is not limited to, a material selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, magnesium aluminosilicate metasilicate, magnesium aluminosilicate, aluminum silicate, sodium silicate, potassium silicate, magnesium silicate, calcium silicate, lactose, lactose monohydrate, lactose anhydrous, calcium hydrogen phosphate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextrin, mannitol, sorbitol, starch, calcium phosphate monohydrate, calcium carbonate, sugars, and any mixture thereof. Any material used as an excipient (diluent) in the art may be included without limitation.
  • the post-mixing unit may further include a lubricant.
  • the lubricant included in the post-mixing unit may be included in an amount of 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1 wt%, 0.5 to 5 wt%, 0.5 to 3 wt%, 0.5 to 2 wt%, or 0.5 to 1 wt% based on the total weight of the pharmaceutical combination preparation, but is not limited thereto.
  • the lubricant included in the post-mixing section may be included in an amount of 0.1 to 20 wt%, 0.1 to 15 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 2 wt%, 0.5 to 20 wt%, 0.5 to 15 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, or 0.5 to 2 wt% based on the total weight of the post-mixing section, but is not limited thereto.
  • the post-mixing unit may include an additive selected from microcrystalline cellulose, lactose monohydrate, mannitol, crospovidone, magnesium stearate, and any combination thereof.
  • additives may be additionally mixed into the granular portion and/or post-mixing portion, if necessary.
  • additives include, but are not limited to, stabilizers, solubilizers, sweeteners, flavoring agents, pigments, humectants, fillers, stabilizers, surfactants, lubricants, solubilizers, buffers, sweeteners, adsorbents, flavoring agents, binders, suspending agents, curing agents, antioxidants, brighteners, flavoring agents, flavoring agents, pigments, coating agents, humectants, moisture regulators, fillers, antifoaming agents, refreshing agents, chewing agents, antistatic agents, coloring agents, sugar coating agents, isotonic agents, softeners, emulsifiers, adhesives, thickeners, foaming agents, pH regulators, excipients, dispersants, disintegrants
  • the present invention may further include an outer coating layer on at least one surface of the composite formulation, if necessary.
  • the outer coating layer may include a coating agent.
  • the coating agent may use a polymer commonly used in the art, and non-limiting examples thereof include methylcellulose, ethylcellulose, polyvinylacetic acid, polyvinyl alcohol, polyvinylacetic acid, polyvinylpyrrolidone, povidone, methacrylic acid-ethyl acrylate copolymer, triacetin, propylene glycol, hydroxyethylcellulose, hydroxypropyl methylcellulose, etc., or OpadryTM sold by Colorcon may be used as the coating agent.
  • a polymer commonly used in the art and non-limiting examples thereof include methylcellulose, ethylcellulose, polyvinylacetic acid, polyvinyl alcohol, polyvinylacetic acid, polyvinylpyrrolidone, povidone, methacrylic acid-ethyl acrylate copolymer, triacetin, propylene glycol, hydroxyethylcellulose, hydroxypropyl methylcellulose, etc., or OpadryTM sold by Colorcon
  • the outer coating layer of the present invention may additionally include various biologically inactive ingredients for additional purposes such as coating efficiency, drug stability, appearance, color, protection, maintenance, binding, performance improvement, and manufacturing process improvement.
  • the biologically inactive ingredients that may be additionally included in the outer coating layer may be at least one selected from the group consisting of plasticizers, lubricants, colorants, flavoring agents, surfactants, stabilizers, antioxidants, foaming agents, anti-foaming agents, paraffin, and wax, but are not limited thereto.
  • the amount of the outer coating layer or the coating agent used is preferably kept to a minimum to provide an optimal formulation size and ensure effective manufacturing.
  • the coating agent may be included in an amount ranging from 0.1 to 20 wt%, preferably from 1 to 5 wt%, based on the total weight of the pharmaceutical combination formulation, but is not limited thereto.
  • the combination formulation according to the present invention contains all three pharmacologically active ingredients, ezetimibe, rosuvastatin, and empagliflozin, in a single formulation, thereby alleviating the inconvenience of having to take two separate formulations for the treatment of dyslipidemia and diabetes and significantly improving patient convenience in taking the medication.
  • the combination formulation may be administered once daily, twice daily, three times daily, or four times daily, depending on the content of the main ingredients contained.
  • the combination preparation of the present invention may be a preparation for oral administration.
  • the combination preparation of the present invention may be in the form of a single preparation, a pellet, a capsule, a single-layer tablet, a double-layer tablet, a multi-layer tablet, an inner-core tablet, a drug-coated tablet, a powder, or a granule, and the capsule may be a polycap or a drug-coated capsule.
  • the combination preparation of the present invention may be in the form of a single-layer tablet, but is not limited thereto.
  • the total weight of the combination preparation of the present invention may be, but is not limited to, 400 to 1,000 mg, 450 to 1,000 mg, 500 to 1,000 mg, 400 to 900 mg, 450 to 900 mg, 500 to 900 mg, 400 to 800 mg, 450 to 800 mg, 500 to 800 mg, 400 to 700 mg, 450 to 700 mg, 500 to 700 mg, 400 to 600 mg, 450 to 600 mg or 500 to 600 mg.
  • the combination preparation according to the present invention has a therapeutic synergy effect according to the combined use of ezetimibe, rosuvastatin, and empagliflozin, and can prevent delay in drug release and reach the target dissolution rate.
  • the combination preparation according to the present invention is characterized in that, in a dissolution test (pH 6.8 solution + 0.1% polysorbate, 37°C, 900 mL, 75 rpm), the dissolution rate of ezetimibe is 40% or more, 45% or more, or 50% or more within 10 minutes, 50% or more, 55% or more, or 60% or more within 15 minutes, 65% or more, 70% or more, or 75% or more within 30 minutes, 70% or more, 75% or more, or 80% or more within 45 minutes, and 80% or more, 85% or more, or 90% or more within 1 hour.
  • a dissolution test pH 6.8 solution + 0.1% polysorbate, 37°C, 900 mL, 75 rpm
  • the compound preparation according to the present invention is characterized in that, in a dissolution test (pH 1.2 solution, 37°C, 900 mL, 50 rpm), the dissolution rate of rosuvastatin is 60% or more, 70% or more, 75% or more, or 80% or more within 5 minutes, 75% or more, 80% or more, 85% or more, or 90% or more within 10 minutes, 80% or more, 85% or more, or 90% or more within 15 minutes, 85% or more, 90% or more, or 95% or more within 30 minutes, and 90% or more or 95% or more within 45 minutes.
  • a dissolution test pH 1.2 solution, 37°C, 900 mL, 50 rpm
  • the compound preparation according to the present invention is characterized in that, in a dissolution test (pH 1.2 solution, 37°C, 900 mL, 50 rpm), the dissolution rate (based on weight) of empagliflozin is 45% or more, 50% or more, 60% or more, 70% or more, or 80% or more within 5 minutes, 65% or more, 70% or more, 75% or more, or 80% or more within 10 minutes, 75% or more, 80% or more, 85% or more, or 90% or more within 15 minutes, 85% or more, 90% or more, or 95% or more within 30 minutes, and 85% or more, 90% or more, or 95% or more within 45 minutes.
  • a dissolution test pH 1.2 solution, 37°C, 900 mL, 50 rpm
  • (c) It may include a step of mixing the granular portion and the post-mixed portion to prepare a solid preparation.
  • steps (a) and (b) do not necessarily have to be performed sequentially, and step (b) may be performed after step (a), or step (a) may be performed after step (b), or steps (a) and (b) may be performed simultaneously.
  • the step of preparing the granule portion (a) may include the step of preparing a mixture for preparing granules by mixing ezetimibe or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive; and the step of preparing granules (a-2).
  • the pharmaceutically acceptable additive mixed with the active ingredient in the step (a-1) may include at least one selected from the group consisting of a disintegrant, an excipient (diluent), a lubricant, and a binder, but preferably includes an excipient (diluent), a disintegrant, and a lubricant.
  • the granule manufacturing step (a-2) can be performed according to any granule manufacturing method known in the art, and can be performed, for example, by a wet granulation method.
  • Ezetimibe is a poorly soluble drug that exhibits a low saturation solubility of about 1 ppm in both acidic and weakly alkaline body fluid conditions. Saturated solubility and the dissolution rate from the start of dissolution to saturation can be important indicators for evaluating the bioavailability of poorly soluble drugs.
  • ezetimibe by manufacturing the granules containing the ezetimibe as wet granules, ezetimibe can reach saturation solubility at a faster rate, ultimately increasing the bioavailability of ezetimibe.
  • the wet granulation method may be performed using a fluid bed granulator, or may be performed using a high speed mixer, etc.
  • the wet granulation when wet granulation is performed using a fluidized bed granulator, the wet granulation can be performed by specifically suspending the granule-making mixture in the fluidized bed granulator and spraying a binding coating solution thereon. If necessary, an additional drying process can be performed.
  • the binding coating solution used in the wet granulation process of the present invention can be prepared by dissolving a binding agent in a solvent.
  • the type of solvent used is not particularly limited, but may include, for example, water, ethanol, isopropanol, acetone, or a combination thereof.
  • a step of crushing or sizing the granules using a crusher (fitzmill), an oscillator, etc. may be additionally included, if necessary.
  • the step of preparing the post-mixing portion (b) may be performed by mixing rosuvastatin/empagliflozin or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable additive.
  • the pharmaceutically acceptable additive mixed with the active ingredient in step (b) may be at least one selected from the group consisting of a disintegrant, an excipient (diluent), and a lubricant, and preferably may include an excipient (diluent) and a disintegrant, and may further include a lubricant.
  • step (b) may be performed by first mixing the active ingredient, excipients, and disintegrant, and then second mixing the lubricant, but is not limited thereto.
  • step (b) may be performed by mixing the active ingredient, disintegrant, excipient (diluent), and lubricant together, but is not limited thereto.
  • the disintegrant may be added during the preparation of the mixed powder for preparing granules (a-1) and/or during the preparation of the post-mixing section (b).
  • the disintegrant may be added during the preparation of the mixed powder for preparing granules (a-1)
  • the disintegrant may be added during the preparation of the post-mixing section (b)
  • the disintegrant may be added during the preparation of the mixed powder for preparing granules (a-1), and also during the preparation of the post-mixing section (b).
  • the step of formulating into a solid formulation (c) may be performed by a tableting process, but is not limited thereto, and may be appropriately adjusted depending on the desired formulation.
  • the tableting machine used in the tableting process is not particularly limited as long as it is a device that typically manufactures pharmaceutically compressed products, and a known tableting machine such as a rotary tableting machine or a single-shot tableting machine can be used.
  • the appropriate hardness of the tablets manufactured by the tableting process before forming the film coating layer can be, for example, 1 to 30 kp.
  • the tablet obtained after the pressing in the step (c) can be manufactured in various shapes, for example, oval, rectangular, egg-shaped, triangular, almond-shaped, peanut-shaped, parallelogram-shaped, circular, pentagonal, hexagonal or trapezoidal, preferably circular, egg-shaped or parallelogram-shaped.
  • a step of coating the outer surface of the tablet obtained after the tableting process in step (c) may be additionally included using a coating solution containing a coating agent.
  • the coating solution can be prepared by dissolving the coating agent in a solvent.
  • solvents that can be used include, but are not limited to, ethanol, methanol, acetone, acetonitrile, tetrahydrofuran, hexane, methylene chloride, isopropyl alcohol, water, and mixtures thereof.
  • one or more selected from the group consisting of plasticizers, lubricants, colorants, flavoring agents, surfactants, stabilizers, antioxidants, foaming agents, antifoaming agents, paraffin, and waxes may be additionally mixed and used.
  • the coating can be performed using a conventional method used in the art for coating drugs, for example, a coating method using a pan coater can be used, but is not limited thereto.
  • a binding coating solution (a solution of 4 mg of povidone dissolved in 90 mg of water) was prepared separately by dissolving povidone in purified water, and the granule mixture, ezetimibe, sodium lauryl sulfate, croscarmellose sodium, lactose monohydrate, and microcrystalline cellulose, was prepared by mixing them.
  • the granule mixture was fed into a fluidized bed granulator and fluidized.
  • the machine was operated at an inlet temperature of 65 °C and a spray pressure of 1500 mbar, and a spray rate of 750 g/min was used to inject the povidone binding coating solution.
  • the granules were assembled under the same initial conditions, and then the inlet temperature was increased to 75 °C during drying, and then drying was performed. After drying, the granules were sieved through a sieve with a mesh size of 30 (0.6 mm) to produce ezetimibe wet granules (wet granulation section).
  • the manufactured ezetimibe wet granules were post-mixed with rosuvastatin calcium salt, empagliflozin, microcrystalline cellulose, D-mannitol, lactose monohydrate, and crospovidone, and then sodium stearyl fumarate was mixed therewith to prepare a final mixed mixture (post-mixing section).
  • the obtained final mixture was compressed into tablets using a tableting machine (AUTOTAB-200TR, Ichihashi Seiki) to produce single-layer tablets (uncoated tablets) having a hardness of approximately 20 KP.
  • a tableting machine AUTOTAB-200TR, Ichihashi Seiki
  • Example 1 Example 2
  • Example 3 Wet granule section Granular mixed powder Ezetimibe 10.0 10.0 10.0 sodium lauryl sulfate 1.0 1.0 1.0 Croscarmellose sodium 6.5 6.5 6.5 lactose monohydrate 16.0 16.0 16.0 microcrystalline cellulose 44.5 44.5 44.5 combination solution povidone 2.0 2.0 2.0
  • Post-mixing section Post-mixed powder Rosuvastatin calcium (as rosuvastatin) 10.4 (10.0) 10.4 (10.0) 10.4 (10.0) 10.4 (10.0)
  • a triple-combination single tablet of ezetimibe, rosuvastatin, and empagliflozin was manufactured by performing the same procedure as in Examples 1 to 3 above, but adjusting the content of empagliflozin and excipients as shown in Table 2 below.
  • the dissolution evaluation of empagliflozin and rosuvastatin was performed in a pH 1.2 solution for the combined formulations of Examples 1 to 3 and Comparative Examples 1 and 2.
  • the specific dissolution test conditions are as follows, and the dissolution test solution samples were collected at 0, 5, 10, 15, 30, and 45 minutes after the start of the test, and the change in the dissolution rate was measured by performing liquid chromatography, and the results are shown in Tables 3 and 4 below and Figs. 1 and 2.
  • Dissolution test solution Rosuvastatin calcium and empagliflozin (pH 1.2 buffer, 900 mL)
  • Rotation speed Rosuvastatin calcium and empagliflozin (50 rpm)
  • the tablets of Examples 1 to 3 in which empagliflozin was included in the post-mixing portion in an amount of 1.5 to 8 wt% based on the total weight of the tablet, and the excipient (diluent) was included in the post-mixing portion in an amount of 60 to 90 wt% based on the total weight of the tablet, exhibited a dissolution rate of empagliflozin equivalent to that of the control drug containing only empagliflozin (Control Example 2).
  • empagliflozin itself is sticky and has the property of easily agglomerating, and in the tablets of Comparative Examples 1 and 2, the content of empagliflozin in the post-mixing section was high and the content of excipients was relatively low, so it is interpreted that empagliflozin was tightly agglomerated in the dissolution port, resulting in a low dissolution rate.
  • Example 4 Example 5
  • Example 6 Example 7
  • Example 8 Wet granule section Granular mixed powder Ezetimibe 10.0 10.0 10.0 10.0 10.0 sodium lauryl sulfate 1.0 1.0 1.0 1.0 1.0 1.0 Croscarmellose sodium 6.5 6.5 6.5 6.5 6.5 lactose monohydrate 16.0 16.0 16.0 16.0 microcrystalline cellulose 44.5 44.5 44.5 44.5 44.5 combination solution povidone 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
  • Post-mixing section Post-mixed powder Rosuvastatin calcium (as rosuvastatin) 5.2 (5.0) 2.6 (2.5) 10.4 (10.0) 5.2 (5.0) 2.6 (2.5)
  • the dissolution evaluation of rosuvastatin and empagliflozin was performed in a pH 1.2 solution for the combination formulations of Examples 4 to 8, and the dissolution evaluation of ezetimibe was performed in a pH 6.8 solution.
  • the dissolution evaluation was also performed for the combination formulation of Example 2 to confirm the change in dissolution rate according to the content of the excipient.
  • the dissolution test conditions of rosuvastatin and empagliflozin were the same as those described in Experimental Example 1, and the dissolution test conditions of ezetimibe were as follows. Dissolution test liquid samples were collected at 0, 5, 10, 15, 30, and 45 minutes after the start of the test, and the change in dissolution rate was measured by liquid chromatography, and the results are shown in Tables 6 to 8 and Figures 3 to 5 below.
  • Example 10 Example 11 Wet granule section Granular mixed powder Ezetimibe 10.0 10.0 10.0 sodium lauryl sulfate 1.0 1.0 1.0 Croscarmellose sodium 6.5 6.5 6.5 lactose monohydrate 16.0 16.0 16.0 microcrystalline cellulose 44.5 44.5 44.5 combination solution povidone 2.0 2.0 2.0 Post-mixing section Post-mixed powder Rosuvastatin calcium (as rosuvastatin) 10.4 (10.0) 10.4 (10.0) 10.4 (10.0) 10.4 (10.0) Empagliflozin 25.0 25.0 25.0 microcrystalline cellulose 130.0 130.0 130.0 130.0 D-mannitol 129.5 120.0 105.0 lactose monohydrate 129.5 120.0 105.0 Crospovidone 1.2 20.2 50.2 magnesium stearate 4.4 4.4 4.4 4.4 Total weight of 1 tablet (mg/T) 510.0 510.0 510.0 510.0
  • the dissolution evaluation of rosuvastatin and empagliflozin was performed in a pH 1.2 solution for the combined formulations of Examples 2 and 9 to 11 and Comparative Example 3.
  • the dissolution test conditions for rosuvastatin and empagliflozin were the same as those described in Experimental Example 1, and the dissolution test liquid samples were collected at 0, 5, 10, 15, 30, and 45 minutes after the start of the test, and the change in dissolution rate was measured by performing liquid chromatography, and the results are shown in Tables 11 and 12 below, and Figures 6 and 7.
  • the tablets of Examples 2 and 9 to 11 showed dissolution profiles comparable to those of the control drug for both empagliflozin and rosuvastatin.
  • the tablet of Comparative Example 3 which used a small amount of disintegrant in the granule portion and post-mix portion, showed very low initial dissolution rates for empagliflozin and rosuvastatin.
  • Friability evaluation was conducted on the tablets manufactured in Examples 2, 10, and 11 and Comparative Example 4, and the results are shown in Table 13 below.
  • 100-time friability is used as an evaluation item to check for tableting problems in the tableting process
  • 400-time friability is used as an evaluation item to ensure tablet stability in the coating machine.
  • the evaluation standard for 100-time friability is within 0.2%
  • the evaluation standard for 400-time friability is within 1%.
  • Example 2 Example 10
  • Example 11 Comparative Example 4 Disintegrant content (granular part/post-mixed part) 8.13 wt%/ 2.37 wt% 8.13 wt%/ 4.70 wt% 8.13 wt%/ 11.67% by weight 8.13 wt%/ 18.65% by weight 100 times wear (within 0.2%) 0.01 0.07 0.18 0.56 400 times wear (within 1.0%) 0.08 0.20 0.80 1.52
  • a 2x2 crossover test was conducted on six beagle dogs divided into two groups. After oral administration of the tablets of Example 2 (10/10/25 mg) and Control Example 1 (10/10 mg) + Control Example 2 (25 mg) once each, blood samples were collected to measure the blood concentrations of ezetimibe/rosuvastatin/empagliflozin.
  • Example 2 a triple combination single tablet of ezetimibe, rosuvastatin, and empagliflozin, was administered, it was confirmed that the AUC, Cmax, and Tmax parameters were statistically bioequivalent to those of the commercially available ezetimibe/rosuvastatin calcium combination preparation (Rosujet Tablet TM ; Control Example 1) and the empagliflozin single tablet (Jardiance Tablet TM ; Control Example 2).
  • the triple combination preparation of ezetimibe, rosuvastatin, and empagliflozin according to the present invention can be used instead of single administration of these drugs as separate preparations, thereby significantly improving the convenience of taking the drug for patients.
  • the present invention is applicable to a combination preparation comprising ezetimibe, rosuvastatin, and empagliflozin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une préparation d'association pharmaceutique, qui comprend de l'ézétimibe, de la rosuvastatine et de l'empagliflozine en tant que principes actifs, et peut ainsi être administrée sous la forme d'un seul médicament, et non par coadministration, dans le traitement simultané de la dyslipidémie et du diabète, ce qui permet d'améliorer la commodité d'administration au patient, d'affecter de manière minimale la dissolution entre les médicaments, d'assurer une équivalence biologique et de présenter une excellente stabilité des principes actifs.
PCT/KR2025/006173 2024-05-08 2025-05-08 Préparation d'association contenant de l'ézétimibe, de la rosuvastatine et de l'empagliflozine avec observance thérapeutique améliorée Pending WO2025234781A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2024-0060726 2024-05-08
KR1020240060726A KR20250161310A (ko) 2024-05-08 2024-05-08 복약순응도가 개선된 에제티미브, 로수바스타틴 및 엠파글리플로진을 포함하는 복합제제

Publications (1)

Publication Number Publication Date
WO2025234781A1 true WO2025234781A1 (fr) 2025-11-13

Family

ID=97675575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2025/006173 Pending WO2025234781A1 (fr) 2024-05-08 2025-05-08 Préparation d'association contenant de l'ézétimibe, de la rosuvastatine et de l'empagliflozine avec observance thérapeutique améliorée

Country Status (2)

Country Link
KR (1) KR20250161310A (fr)
WO (1) WO2025234781A1 (fr)

Also Published As

Publication number Publication date
KR20250161310A (ko) 2025-11-17

Similar Documents

Publication Publication Date Title
WO2015102400A1 (fr) Préparation composite pour une administration orale comportant de l'ézétimibe et de la rosuvastatine
WO2009134086A2 (fr) Préparation pharmaceutique pour le traitement d'une maladie cardiovasculaire
WO2017007287A1 (fr) Composition pharmaceutique contenant l'amlodipine, le valsartan et la rosuvastatine
WO2019182276A1 (fr) Préparation d'une association de produits pharmaceutiques comprenant de l'ézétimibe et de la rosuvastatine
WO2019221473A1 (fr) Composition pharmaceutique comprenant un inhibiteur de sglt-2 et un inhibiteur de dpp-iv
WO2024248513A1 (fr) Dispersion solide d'inhibiteurs de kinome myéloïde et composition pharmaceutique la comprenant
WO2020130502A1 (fr) Composition pharmaceutique comprenant l'empagliflozine et la sitagliptine
WO2009104939A2 (fr) Préparation pharmaceutique
WO2020009352A1 (fr) Préparation pharmaceutique contenant de la dapagliflozine/l-proline amorphe et son procédé de préparation
WO2010008244A2 (fr) Préparation pharmaceutique
WO2019031898A2 (fr) Composition pharmaceutique et sa méthode de préparation
WO2025234781A1 (fr) Préparation d'association contenant de l'ézétimibe, de la rosuvastatine et de l'empagliflozine avec observance thérapeutique améliorée
WO2018151580A1 (fr) Préparation pharmaceutique à libération immédiate et à libération prolongée contenant du chlorhydrate d'itopride
WO2019245150A1 (fr) Composition pharmaceutique comprenant du cilostazol et un médicament à base de statine
WO2015012633A1 (fr) Formulation complexe contenant de la metformine à libération prolongée et un inhibiteur de la hmg-coa réductase à libération immédiate
WO2016209061A1 (fr) Préparation composite de mosapride et de rabéprazole
WO2016052866A1 (fr) Composition pharmaceutique solide comportant de l'amlodipine et du losartan
WO2018062964A1 (fr) Capsule composite contenant de la vitamine d ou un dérivé de celle-ci, et du raloxifène ayant un taux de dissolution amélioré, et son procédé de préparation
WO2015093859A1 (fr) Préparation pharmaceutique combinée contenant un inhibiteur de hmg-coa réductase et un inhibiteur de l'absorption du cholestérol
WO2018199636A1 (fr) Formulation combinée comprenant un inhibiteur de la hmg-coa réductase et un bloqueur des canaux calciques
WO2009134056A9 (fr) Formulation pharmaceutique
WO2013169082A1 (fr) Préparation orale à libération contrôlée de bosentan
WO2009125944A2 (fr) Préparation pharmaceutique contenant un inhibiteur des canaux calciques non dihydropyridine et un inhibiteur du récepteur de l'angiotensine 2
WO2023132699A1 (fr) Comprimé à libération prolongée de carvédilol à conformité améliorée par réduction de la taille de comprimé à l'aide d'une technologie de comprimé à faible excipient ilet (innovation à faible excipient)
WO2024210557A1 (fr) Formulation combinée comprenant du sacubitril-valsartan et un inhibiteur de sglt-2 ayant une stabilité et un taux de dissolution améliorés